Geoffrey D. Huntley

Geoffrey D. Huntley

Auto-generated profile, based on publicly available information

Geoffrey D. Huntley

Department of Cardiovascular Medicine Mayo Clinic Rochester MN

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EFEmily J Farrar
Emily J Farrar
GHGeoffrey D Huntley
Geoffrey D Huntley
JBJonathan Butcher
Jonathan Butcher
Oxidative stress is present in and contributes to calcification of the aortic valve, but the driving factors behind the initiation of valve oxidative stress are not well understood. We tested whether the valve endothelium acts as an initiator and propagator of oxidative stress in aortic valve disease. Calcified human aortic valves showed side-specific elevation of superoxide in the endothelium, co-localized with high VCAM1 expression, linking oxidative stress, inflammation, and valve degeneration. Treatment with inflammatory cytokine TNFα increased superoxide and oxidative stress and decreased eNOS and VE-cadherin acutely over 48 hours in aortic valve endothelial cells (VEC) and chronically over 21 days in ex vivo AV leaflets. Co-treatment of VEC with tetrahydrobiopterin (BH4) but not apocynin mitigated TNFα-driven VEC oxidative stress. Co-treatment of ex vivo AV leaflets with TNFα+BH4 or TNFα+peg-SOD rescued endothelial function and mitigated inflammatory responses. Both BH4 and peg-SOD rescued valve leaflets from the pro-osteogenic effects of TNFα treatment, but only peg-SOD was able to mitigate the fibrogenic effects, including increased collagen and αSMA expression. Aortic valve endothelial cells are a novel source of oxidative stress in aortic valve disease. TNFα-driven VEC oxidative stress causes loss of endothelial protective function, chronic inflammation, and fibrogenic and osteogenic activation, mitigated differentially by BH4 and peg-SOD. These mechanisms identify new targets for tailored antioxidant therapy focused on mitigation of oxidative stress and restoration of endothelial protection.

3 October 2017 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
GHGeoffrey D. Huntley
Geoffrey D. Huntley
JTJeremy J. Thaden
Jeremy J. Thaden
SASaid Alsidawi
Said Alsidawi
HMHector I Michelena
Hector I Michelena
JMJoseph J. Maleszewski
Joseph J. Maleszewski
VNVuyisile T. Nkomo
Vuyisile T. Nkomo
To examine differences and similarities in bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) stenosis occurring during the same age and whether any differences impact outcomes following aortic valve replacement (AVR). An age-matched cohort of 198 BAV stenosis and 198 TAV stenosis patients was identified from 888 consecutive patients undergoing AVR for severe AS. Mean age 68 ± 6 years; 68% male. Patients with BAV were less likely to have multiple comorbidities, as measured by the Charlson Comorbidity Index (CCI) >2 (3 vs. 10%, P = 0.007). Indexed aortic valve area (0.44 ± 0.09 vs. 0.42 ± 0.08 cm2/m2, P = 0.17) and left ventricular ejection fraction (LVEF) were similar (62 ± 11 vs. 61 ± 12%, P = 0.12), but E/e’ ≥15 (46 vs. 66%, P = 0.0002) was less common in BAV stenosis. A tissue aortic valve prosthesis was more commonly utilized in both groups (81 vs. 78%, P = 0.54). Overall indexed effective orifice area was larger in BAV compared with TAV (1.08 ± 0.33 vs. 0.96 ± 0.25 cm2/m2, P = 0.0008). Five-year survival following AVR was lower in TAV compared with BAV stenosis (61 vs. 79%, P = 0.02). Independent predictors of survival following AVR were LVEF < 50% [hazard ratio (HR): 4.8, P = 0.0005], CCI > 2 (HR: 3.1, P = 0.015), effective orifice area index ≤0.85 cm2/m2 (HR: 2.5, P = 0.004), and bioprosthesis (HR: 3.7, P = 0.02). In an age-matched cohort, TAV compared with BAV stenosis is associated with greater prevalence of cardiovascular risk factors and cardiac impairment and worse survival after AVR.

1 December 2017 in American Heart Journal
Verified
Journal Article
Closed access
AEAlexander C. Egbe
Alexander C. Egbe
GHGeoffery D. Huntley
Geoffery D. Huntley
HCHeidi M. Connolly
Heidi M. Connolly
NANaser M. Ammash
Naser M. Ammash
ADAbhishek J. Deshmukh
Abhishek J. Deshmukh
SKSuraj Kapa
Suraj Kapa

14 June 2018 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
GHGeoffrey D. Huntley
Geoffrey D. Huntley
ADAbhishek J. Deshmukh
Abhishek J. Deshmukh
CWCarole A. Warnes
Carole A. Warnes
SKSuraj Kapa
Suraj Kapa
AEAlexander C. Egbe
Alexander C. Egbe

20 July 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
GHGeoffrey D. Huntley
Geoffrey D. Huntley
DDDavid A. Danford
David A. Danford
JMJonathan Menachem
Jonathan Menachem
SKShelby Kutty
Shelby Kutty
ACAri Cedars
Ari Cedars
Background: Patients with adult congenital heart disease (ACHD) experience long waitlist times for heart transplantation (HTx) while a large proportion of donor hearts are refused. The goal of this study was to inform optimal donor selection for patients with ACHD listed for HTx by examining the impact of donor characteristics on post‐HTx outcomes. Methods and Results: Using the Scientific Registry of Transplant Recipients, we conducted a retrospective analysis of patients aged ≥18 years listed for HTx in the United States between 2000 and 2016. We compared waitlist times between patients with ACHD and patients with noncongenital heart disease and constructed multivariate hazard models to identify donor characteristics associated with increased waitlist time. We then compared post‐HTx survival between patients with ACHD and patients with noncongenital heart disease and constructed multivariate hazard models to identify donor characteristics associated with mortality. There were very few differences in donor characteristics between HTx recipients with ACHD and those with noncongenital heart disease. Status 1A–listed patients with ACHD experienced longer waitlist times compared with patients with noncongenital heart disease. Increased wait times were associated with some donor characteristics. Post‐HTx outcomes varied over time, with patients with ACHD having inferior early mortality (0 to 30 days), similar intermediate mortality (31 days to 4 years), and superior late mortality (>4 years). We identified no donor characteristics associated with mortality to justify the observed differences in donor selection or waitlist time. Conclusions: HTx candidates with ACHD wait longer for transplant but do not require unique donor selection criteria. HTx teams should consider liberalizing donor criteria and focusing only on evidence‐based selection to improve waitlist outcomes and reduce the recipient–donor disparity.

18 May 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EFEmily J. Farrar
Emily J. Farrar
GHGeoffrey D. Huntley
Geoffrey D. Huntley
JBJonathan Butcher
Jonathan Butcher
[This corrects the article DOI: 10.1371/journal.pone.0123257.].